Economists please meet the idea of multiple causality. Insufficient supply of vaccines IS driven by WTO rules & IP monopolies. It's not the ONLY cause. We also need tech transfer & funding & more @ATabarrok gets so many things here wrong…
a quick list🧵 marginalrevolution.com/marginalrevolu…
“Licenses are widely available” They are not. Most of the world has been dependent on ONE exclusive license to ONE manufacturer, Serum Institute. Many other high-quality firms could be making vaxs but monopoly holders said no. Because of monopoly they can. 2/11
“J&J’s vaccine has been licensed for production in… South Africa.” Nope.
One company has a “fill and finish” contract with J&N in SA. They have been been given the right or the tech to make the full vax or distribute on their own. Sub-contractors are not what’s needed here 3/11
“All of the vaccine manufacturers are trying to increase supply as quickly as possible”
No they simply are not. Multiple firms around the world have asked for & could be making vaccines but have been denied that right by monopoly holders 4/11
“Plastic bags are a bigger bottleneck than patents"
👏Great line. But do you know how global IP works?
Point is these are now proprietary processes, combo of IP mean supply chains are monopolized & secretive. It’s all related. Need to produce more bags too—let’s get on it 5/11
“Moderna has said that they won’t enforce their patents during the pandemic but no one has stepped up to produce because no one else can” This defies logic and evidence.
Multiple firms can: Lonza, for example, Moderna contracted, did tech transfer, producing within months…6/11
…implication of course is that producers in low- and middle-income countries can’t. Moderna & BioNTech?Start-ups with little manufacturing expertise. Meanwhile in India, South Africa, Thailand, Brazil, Vietnam, global companies with powerhouse expertise
Let them all produce 7/11
“US trade representative’s announcement is virtue signaling”
I know this is hard to believe but this is not about you or the USTR. The governments of South Africa, India, and 62 countries co-sponsoring resolution are not the “anti-market left” but govts facing pandemic... 8/11
...they along with the head of the World Health Organization AND the World Trade Organization have said this is a good move. And NOBODY thinks this in the ONLY move (repeat after me: multiple causality).
Stop with the straw arguments. 9/11
An IP waiver is actually a very limited, conservative idea that is only one part of the puzzle—but it is a key piece of the puzzle as we argued: washingtonpost.com/opinions/2021/…
10/11
^TYPO! They have NOT been been given the right or the tech to make the full vax or distribute on their own.
*fixing impt typo above😣 Aspen in SAfrica has NOT been given right or tech to make full vax or distribute independently. That's the point here--the monopoly prevents Aspen from doing what it does with ARVs--make them, sell them throughout Africa.
And check out this great piece showing exactly how our “plastic bag” problem is actually a monopoly problem.
Even I was surprised there are 2,800 patents on single-use bioreactor bags
Governments can do multiple things at once on global #COVIDVaccine access. At risk of over-political-scienceing: Need to disntinguish 2 agenda-setting arguments re WTO waiver as "distraction"
-Govts can't do waiver and X (not a real argument)
-Govts might use to distract (fair)
We know (takes Baum&Jones off shelf) govts have limited political attention:
Aside: FAR too little focus on political strategy for vaccine equity. I see this as core prob of COVAX. Political agenda occupied by sharing doses (implausible) instead of knowledge to produce.
But PLENTY of political attention to both do TRIPS waiver and do tech transfer + funding. WTO negotiations will be done by trade ministers/reps with significant capacity. Issues are straightforward. I can say talking to USG, WH+State+HHS have plenty capacity to walk + chew gum.
Richard Epstein says @MadhaviSunder & I are “panglossian” in calling for waiving TRIPS obligations as a piece of vaccine access puzzle. Doing so he provides great summary of baseless arguments against.
Steeped in misinformation and neocolonialism.
Retro to HIV circa 2000...🧵
1: Africans, Asians, LatAmers cant vaccinate:
RE:“Local players—such as doctors, health care officials, pharmacists, transportation officials, & many more—all must be able to efficiently utilize these US technologies for any program to work. Do they have the capacity to do that?"
…Remarkable. If exact same hadn't been said on HIV in Africa I would be surprised. Yes, despite health systems weaknesses low&mid-income country healthworkers can provide vaccines. Yes cold-chain is tricky. Yes it can be, has been, will be done
The new "Africans cant tell time"
The #TRIPSWaiver: lots of misunderstanding & mis-information on WTO & law.
A thread on why it's:
-not going to harm innovation
-not radical
- harmful to pretend it is
-not going to touch US pharma patents
-(as we all said) just 1 piece of #CovidVaccine access puzzle
🧵1/14
1)Those arguing TRIPS waiver will undermine the innovation that got us #COVIDVaccines are asking us to believe start-ups (Moderna, BioNTech) and universities (Oxford, UPenn) are going to stop taking public money to develop & trial breakthrough vaccines (!?) or 2/12
or that major pharma companies are going to refuse to commercialize technologies with huge potential rewards ($billions from massive orders) that have largely been de-risked by public + philanthropic efforts if they are only promised monopolies in US, EU and other HICs… 3/14
How much longer 'til we remove barriers to LMIC vax produc? Argument against: might slow down HIC production? Given inequity @POTUS has to see now the urgency.
Quick 🧵 what I and others have written. If we'd seen action, might be factories running today.
No more delays.../1
July 2020: @CyrilRamaphosa & heads of state + world leaders called for open sharing of vaccine science for global production. We've seen that companies like @moderna_tx@BioNTech_Group@pfizer have set up whole new factories in 3-6 months.
Imagine if we'd started last year... /2
.@JoeBiden must act on vaccine equity. @MadhaviSunder & I argue today @BLaw voluntary measures & donations won't work. USG needs to use leverage of public funding and IP to compel sharing of technology. WTO agreement was premised on tech transfer... news.bloomberglaw.com/us-law-week/bi…
The US is now vaccinating everyone under 16 while older people & frontline health workers in much of the world have no access.
This is bad public health.
Deeply unjust.
And economically damaging @SecYellen said /2 washingtonpost.com/us-policy/2021…
$4 billion to #COVAX is important, but Covax is struggling to reach even an insufficient goal of 20% vaccinations in low- and middle-income countries. Donating $ and surplus vaccines will NOT achieve vaccine equity or halt the pandemic /3
....@USATODAY says it's false because "the vaccine was funded by a combination of government spending, private donations and research grants" and that "$2.5 billion was given for the development of the company's vaccine and to purchase doses" not for research. Nope 🙅.../2
...First, there's the matter of very clear public funding on the front end. 1) NIH scientists directly worked on this (yay them!) along with handing out grants to others to work on this 2) BARDA gave $955m.
✔️Both are taxpayer funding for research.../3